Last reviewed · How we verify

HB-01 — Competitive Intelligence Brief

HB-01 (HB-01) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SIRT6 inhibitor. Area: Metabolic disorders.

phase 2 SIRT6 inhibitor SIRT6 Metabolic disorders Small molecule Live · refreshed every 30 min

Target snapshot

HB-01 (HB-01) — Honeybrains Biotech LLC. HB-01 is a small molecule that targets the SIRT6 protein to modulate cellular metabolism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HB-01 TARGET HB-01 Honeybrains Biotech LLC phase 2 SIRT6 inhibitor SIRT6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SIRT6 inhibitor class)

  1. Honeybrains Biotech LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HB-01 — Competitive Intelligence Brief. https://druglandscape.com/ci/hb-01. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: